HollandBIO welcomes Xinvento as a new member

HollandBIO connects, represents and supports the Dutch life science sector. We are very proud that we already represent over 270 companies: from start-ups, small and medium-sized companies to large companies, active in health, food or biobased economy. Today we welcome Xinvento! Xinvento was founded with the mission to positively impact the lives of those living with congenital hyperinsulinism (CHI). 

CHI is the most frequent cause of hypoglycemia in newborns and children; without proper treatment, it can lead to brain damage or even death. Xinvento is leveraging existing scientific insights with new innovations to develop effective and safe treatments for rare and more common hyperinsulinism diseases. The first program targets CHI. To learn more about our programs, feel free to reach out to us at info@xinvento.com.  

Inspired by love, powered by science – Xinvento BV | Biotech Startup | Congenital Hyperinsulinism 

Curious about recent developments at Xinvento? Dive a little deeper with these two articles: 

https://www.globenewswire.com/en/news-release/2022/04/21/2426081/0/en/Dutch-biotech-Xinvento-raises-seed-round-to-develop-a-treatment-for-the-rare-disease-Congenital-Hyperinsulinism.html

https://fd.nl/bedrijfsleven/1438575/dit-bedrijf-is-echt-opgericht-om-mijn-zoontje-te-helpen